Month: August 2024

CICERO, Ill., Aug. 13, 2024 (GLOBE NEWSWIRE) — Broadwind (Nasdaq: BWEN, or the “Company”), a diversified precision manufacturer of specialized components and solutions serving global markets, today announced results for the second quarter 2024. SECOND QUARTER 2024 RESULTSTotal revenue of $36.5 million Net income of $0.5 million, or $0.02 per diluted share Total non-GAAP adjusted EBITDA of $3.6 million, or 10.0% of total revenue Ratio of net debt to trailing twelve-month non-GAAP adjusted EBITDA of 1.1x as of June 30, 2024Broadwind reported second quarter net income of $0.5 million, or $0.02 per diluted share, versus $1.4 million, or $0.07 per diluted share, in the prior year period. The Company reported adjusted EBITDA, a non-GAAP measure, of $3.6 million in the second quarter compared to $5.4 million in the prior-year period....

TORONTO, Aug. 13, 2024 (GLOBE NEWSWIRE) — Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and six months ended June 30, 2024. Second Quarter 2024 Summary & Recent Progress:Company continues to execute against Transformational PlanCash used in operations of $1.3 million, down 37% year-over-year and down 54% quarter-over-quarterTotal revenue of $16.6 million, down 17% year-over-year, but in-line with second quarter estimate of at “least $16.5 million”.Gross margin up 62 basis points year-over-year to 71.5%, combined with a 13% decrease in operating expenses year-over-year, drives 3% reduction in GAAP operating loss year-over-year Adjusted EBITDA loss of $4.1 million, up 4% year-over-year, despite 17% revenue...

Management to host a conference call today at 8:30 am ET FLORHAM PARK, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the quarter ended June 30, 2024, and provided a corporate update. “With our recent positive data announcement from the CLOVER WaM pivotal study evaluating iopofosine I 131 in Waldenstrom’s macroglobulinemia, we remain focused on filing our WM NDA in the fourth quarter of this year,” said James Caruso, president and CEO of Cellectar. “We anticipate an accelerated six-month NDA review period and continue to prepare for a potential launch of iopofosine in 2025. We look forward to bringing this meaningful...

TORONTO, Aug. 13, 2024 (GLOBE NEWSWIRE) — Hudbay Minerals Inc. (“Hudbay” or the “company”) (TSX, NYSE: HBM) today released its second quarter 2024 financial results. All amounts are in U.S. dollars, unless otherwise noted. All production and cost amounts reflect the Copper Mountain mine on a 100% basis, with Hudbay owning a 75% interest in the mine. “The continued execution of our operational plans in the second quarter has positioned us well to achieve our 2024 production guidance, and our exposure to gold by-products and strong cost control have allowed us to improve our 2024 cash cost guidance,” said Peter Kukielski, President and Chief Executive Officer. “Our strong and diversified operating base continues to generate free cash flow driven in part by efficient milling performance in Peru and Manitoba. We are also continuing...

MuniFin Group’s Half Year Report January–June 2024: MuniFin’s business operations remained strong during the first half of the year Municipality Finance PlcHalf Year Report13 August 2024 at 1:00 pm (EEST) This release is a summary of MuniFin Group’s Half Year Report published on 13 August 2024. The complete Half Year Report with tables is attached to this release and available at www.kuntarahoitus.fi/en. MuniFin Group has published its Pillar III Half Year Disclosure Report 2024 in accordance with Regulation (EU) No 575/2013 and Directive 2013/36/EU. The report is available at www.kuntarahoitus.fi/en. In brief: MuniFin Group in the first half of 2024The Group’s net operating profit excluding unrealised fair value changes* increased by 9.6% (9.3%) in January–June and amounted to EUR 89 million (EUR 81 million). Net interest income* grew...

Twining Drilling Program is Underway While Optimization InvestmentsMaintain Production and Reduce Operating Costs HONOLULU, Aug. 13, 2024 (GLOBE NEWSWIRE) — Barnwell Industries, Inc. (NYSE American: BRN) today reported financial results for its third fiscal quarter ended June 30, 2024. For the quarter, the Company had revenue of $5,527,000 and a net loss of $1,246,000 or $0.12 per share. In the three months ended June 30, 2023, the Company reported quarterly revenue of $5,675,000 and a net loss of $717,000 or $0.07 per share. The Company remains debt free and ended the quarter with $3,292,000 in working capital, including $4,393,000 in cash and cash equivalents. Continuing Optimization Program is Showing Positive Results Corporate oil and gas production for the current quarter has remained level to the quarter a year ago without...

SHENZHEN, China, Aug. 13, 2024 (GLOBE NEWSWIRE) — Xunlei Limited (“Xunlei” or the “Company”) (Nasdaq: XNET), a leading technology company providing distributed cloud services in China, today announced its unaudited financial results for the second quarter ended June 30, 2024. Second quarter 2024 Financial Highlights:Total revenues were US$79.6 million, representing a decrease of 23.7% year-over-year.  Cloud computing revenues were US$26.4 million, representing a decrease of 13.8% year-over-year.  Subscription revenues were US$32.9 million, representing an increase of 10.8% year-over-year.  Live streaming and other internet value-added services (“Live streaming and other IVAS”) revenues were US$20.3 million, representing a decrease of 53.9% year-over-year.  Gross profit was US$40.7 million, representing...

Q2 2024 revenues were $7.2 million, up 53% from Q2 2023. This was an all-time quarterly record for the Company. Q2 2024 Gross Margin was 73%, vs 74% in Q2 2023 GAAP Operating Income was $2.0 Million Company Provides Guidance for Revenue Growth of 65-75% for Q3 2024 Versus Q3 2023 EDEN PRAIRIE, MN, Aug. 13, 2024 (GLOBE NEWSWIRE) — SANUWAVE Health, Inc. (the “Company” or “SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to provide its financial results for the three months ended June 30, 2024. Q2 2024 ended June 30, 2024Revenue for the three months ended June 30, 2024, totaled $7.2 million, an increase of 53%, as compared to $4.7 million for the same period of 2023.  This growth is within the previous guidance for a 45 – 55% increase. 72 UltraMist® systems...

Received NMPA approval of avatrombopag maleate tablets for the treatment of CLD-associated thrombocytopenia, expanding rare disease product lines Received IND approval from NMPA to evaluate F230 for the treatment of pulmonary arterial hypertension U.S. IND submission for F351 in MASH-associated liver fibrosis expected in late 2024 and data readout from Phase 3 trial in CHB-associated liver fibrosis in the PRC expected by early 2025 Cash and cash equivalents totaled $16.1 million as of June 30, 2024 SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) — Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced financial results for the second quarter ended June 30, 2024 and Year-To-Date 2024, and provided...

~ Achieved Second Quarter 2024 Total Net Revenues of $7.3 Million ~ ~ Appointed Jeffrey S. Hackman as Chief Executive Officer (CEO) and Member of the Board of Directors ~ ~ Company Has Approximately $43 Million in Cash, Cash Equivalents, and Investment Securities ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C., Aug. 13, 2024 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today reported its financial results for the second quarter ended June 30, 2024, and provided a business update. “We continued to execute well in the second quarter and are encouraged by the early third quarter momentum of PEDMARK® within the community oncology and the adolescent and young adult (AYA) population,” said Jeff Hackman, chief executive officer...